Illumina (NASDAQ:ILMN) is a global company dedicated to advancing human health through the discovery, development, and manufacturing of innovative sequencing and array technologies. These cutting-edge technologies serve as the backbone for genetic and genomic research, striving to transform how genetic information is accessed and applied. Illumina's work spans across various fields including oncology, reproductive health, agriculture, and more, aiming to enhance the understanding of genetic variation and function. Their projects often lead the charge in genomic sequencing, contributing significantly to the scientific community's ability to solve complex genetic challenges. Illumina's objectives revolve around driving the progress of genomics into patient care, agriculture, and other critical areas of global health and development, pushing the boundaries of what's possible in the realm of genetics.